Inappropriate Use of Proton Pump Inhibitors for Stress Ulcer Prophylaxis in a Tertiary Care Hospital: A Cross-Sectional Study

三级医院中质子泵抑制剂在应激性溃疡预防中的不合理使用:一项横断面研究

阅读:1

Abstract

BACKGROUND: Although proton pump inhibitors (PPIs) are extensively used for acid-related disorders, their inappropriate administration for stress ulcer prophylaxis (SUP) in hospitalized patients remains a cause for concern. This study aimed to evaluate the extent of PPI misuse for SUP in a tertiary care setting, identify contributing factors, and assess adherence to clinical guidelines. METHODOLOGY: A cross-sectional study was conducted over one year, including hospitalized patients receiving PPIs for SUP without documented indications. Data were collected through medical record reviews and physician questionnaires to determine prescription patterns, indications, and adherence to guidelines. Statistical analysis was performed using SPSS (IBM Corp., Armonk, NY, USA), employing chi-square tests and descriptive statistics. RESULTS: Among 274 patients, only 31.02% had appropriate indications for PPI use, while 68.98% received PPIs without meeting prophylactic criteria. Overall, 33.58% of prescriptions adhered to guidelines, whereas 66.42% deviated. The average duration of PPI use was 10.3 ± 4.7 days: 47.45% used PPIs for seven or fewer days, 31.02% for eight to 14 days, and 21.53% for more than 14 days. Guideline-based prescribing accounted for 35.77%, while 40.88% of prescriptions were attributed to defensive prescribing. Inappropriate PPI use was significantly associated with older age (p = 0.034) and ICU admission (p = 0.001). CONCLUSION: PPI overuse for stress ulcer prevention is prevalent among hospitalized patients. Targeted interventions are needed to improve adherence to evidence-based guidelines and curb unnecessary prescribing, particularly in relation to defensive medical practices.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。